Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on EquityReturn on Sales

Summit Therapeutics (SMMT) Debt Ratio (2018 - 2024)

Historic Debt Ratio for Summit Therapeutics (SMMT) over the last 6 years, with Q1 2024 value amounting to 0.57.

  • Summit Therapeutics' Debt Ratio rose 4418.8% to 0.57 in Q1 2024 from the same period last year, while for Mar 2024 it was 0.57, marking a year-over-year increase of 4418.8%. This contributed to the annual value of 0.49 for FY2023, which is 3382.57% down from last year.
  • According to the latest figures from Q1 2024, Summit Therapeutics' Debt Ratio is 0.57, which was up 4418.8% from 0.49 recorded in Q4 2023.
  • Summit Therapeutics' 5-year Debt Ratio high stood at 0.74 for Q4 2022, and its period low was 0.0 during Q1 2020.
  • Moreover, its 4-year median value for Debt Ratio was 0.41 (2023), whereas its average is 0.39.
  • Data for Summit Therapeutics' Debt Ratio shows a peak YoY increase of 8237.38% (in 2023) and a maximum YoY decrease of 3382.57% (in 2023) over the last 5 years.
  • Over the past 4 years, Summit Therapeutics' Debt Ratio (Quarter) stood at 0.0 in 2020, then surged by 66922.33% to 0.74 in 2022, then plummeted by 33.83% to 0.49 in 2023, then grew by 14.8% to 0.57 in 2024.
  • Its Debt Ratio stands at 0.57 for Q1 2024, versus 0.49 for Q4 2023 and 0.42 for Q2 2023.